4.6 Article

The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization

Journal

PLOS ONE
Volume 10, Issue 10, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0140870

Keywords

-

Funding

  1. American Cancer Society [RSG-14-071-01-TBG]
  2. National Cancer Institute of the National Institutes of Health [P20 CA151129-02]

Ask authors/readers for more resources

Translocation to the nucleus of diacylglycerol kinase (DGK)-zeta is dependent on a sequence homologous to the effector domain of Myristoylated Alanine Rich C-Kinase Substrate (MARCKS). These data would suggest that MARCKS could also localize to the nucleus. A single report demonstrated immunofluorescence staining of MARCKS in the nucleus; however, further experimental evidence confirming the specific domain responsible for this localization has not been reported. Here, we report that MARCKS is present in the nucleus in GBM cell lines. We then over-expressed wild-type MARCKS (WT) and MARCKS with the effector domain deleted (Delta ED), both tagged with V5-epitope in a GBM cell line with low endogenous MARCKS expression (U87). We found that MARCKS-WT localized to the nucleus, while the MARCKS construct without the effector domain remained in the cytoplasm. We also found that over-expression of MARCKS-WT resulted in a significant increase in total cellular phosphatidyl-inositol (4,5) bisphosphate (PIP2) levels, consistent with prior evidence that MARCKS can regulate PIP2 levels. We also found increased staining for PIP2 in the nucleus with MARCKS-WT over-expression compared to MARCKS.ED by immunofluorescence. Interestingly, we observed MARCKS and PIP2 co-localization in the nucleus. Lastly, we found changes in gene expression when MARCKS was not present in the nucleus (MARCKS Delta ED). These data indicate that the MARCKS effector domain can function as a nuclear localization signal and that this sequence is critical for the ability of MARCKS to regulate PIP2 levels, nuclear localization, and gene expression. These data suggests a novel role for MARCKS in regulating nuclear functions such as gene expression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy

Saeed S. Akhand, Hao Chen, Stephen Connor Purdy, Zian Liu, Joshua C. Anderson, Christopher D. Willey, Michael K. Wendt

Summary: T-DM1 efficiently delivers microtubule inhibitor to HER2 overexpressing cells, while induction of EMT may promote emergence of T-DM1 resistant cells.

NPJ BREAST CANCER (2021)

Article Oncology

miR-31 Displays Subtype Specificity in Lung Cancer

Mackenzie L. Davenport, John B. Echols, Austin D. Silva, Joshua C. Anderson, Philip Owens, Clayton Yates, Qing Wei, Shuko Harada, Douglas R. Hurst, Mick D. Edmonds

Summary: miR-31 demonstrates oncogenic properties in specific subtypes of lung cancer, highlighting its potential as a therapeutic target in these subtypes.

CANCER RESEARCH (2021)

Article Medicine, General & Internal

Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease

J. Robert Wong, G. Robert Gish, Ramsey Cheung, S. Amit Chitnis

Summary: The prevalence of vaccination or documented reactivity to hepatitis A antibody and hepatitis B surface antibody among US adults with chronic liver disease is alarmingly low. This is particularly concerning in individuals with nonalcoholic fatty liver disease and alcoholic liver disease.

AMERICAN JOURNAL OF MEDICINE (2021)

Letter Gastroenterology & Hepatology

Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States

Chari Cohen, Kate Moraras, Michalea Jackson, Maureen Kamischke, Robert G. Gish, Carol L. Brosgart, Mehlika Toy, David Hutton, Timothy M. Block, Su Wang, Samuel So

HEPATOLOGY (2022)

Article Oncology

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

Roni Shouval, Ana Alarcon Tomas, Joshua A. Fein, Jessica R. Flynn, Ettai Markovits, Shimrit Mayer, Aishat Olaide Afuye, Anna Alperovich, Theodora Anagnostou, Michal J. Besser, Connie Lee Batlevi, Parastoo B. Dahi, Sean M. Devlin, Warren B. Fingrut, Sergio A. Giralt, Richard J. Lin, Gal Markel, Gilles Salles, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Nishi Shah, Ruth Scherz-Shouval, Marcel van den Brink, Miguel-Angel Perales, Maria Lia Palomba

Summary: TP53 mutations/CNAs are important determinants of response and survival in LBCL patients treated with CD19-CAR-T therapy. TP53 alterations are associated with poor treatment outcomes and lower survival rates.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Gastroenterology & Hepatology

The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?

Yasser Fouad, Jean-Francois Dufour, Ming-Hua Zheng, Steven Bollipo, Hailemichael Desalegn, Henning Gronbaek, Robert G. Gish

Summary: There is a polarizing debate in hepatology regarding the name and redefinition of fatty liver disease associated with metabolic dysfunction. While there is growing evidence supporting the use of the term metabolic (dysfunction) associated fatty liver disease (MAFLD) for clinical and academic practice, controversy remains. This opinion piece argues that understanding scientific consensus and exploring alternative models for reaching agreement are crucial in this field.

LIVER INTERNATIONAL (2022)

Article Physiology

Cardiomyocyte stromal interaction molecule 1 is a key regulator of Ca2+-dependent kinase and phosphatase activity in the mouse heart

Helen E. Collins, Joshua C. Anderson, Adam R. Wende, John C. Chatham

Summary: This study discovered that STIM1 regulates the activity of calcium-dependent kinases and phosphatases in adult mouse hearts. This has important implications for understanding the role of STIM1 in cardiac physiology and pathophysiology.

PHYSIOLOGICAL REPORTS (2022)

Letter Gastroenterology & Hepatology

Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention

Salah Kivlighn, Eric Schuur, Robert G. Gish, Donna Cryer

HEPATOLOGY (2022)

Article Immunology

Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination

Robert J. Wong, Harvey W. Kaufman, Justin K. Niles, Hema Kapoor, Robert G. Gish

Summary: Current treatment eligibility algorithms for chronic hepatitis B are complex and may contribute to missed opportunities for early antiviral therapy. Using a large US laboratory database, we propose a stepwise simplification of chronic hepatitis B treatment eligibility to be considered, aiming to improve timely treatment.

CLINICAL INFECTIOUS DISEASES (2023)

Article Gastroenterology & Hepatology

Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years

Nicolette Veracruz, Robert G. Gish, Ramsey Cheung, Amit S. Chitnis, Robert J. Wong

Summary: The impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) on disability-adjusted life years (DALYs) has shown significant disparities globally. From 2010 to 2019, there has been an overall decrease in DALYs, but differences in DALY improvements across world regions suggest unequal access to viral hepatitis care and treatment.

LIVER INTERNATIONAL (2022)

Review Cell Biology

Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review

Yanina Bogliotti, Mark Vander Roest, Aras N. Mattis, Robert G. Gish, Gary Peltz, Robin Anwyl, Salah Kivlighn, Eric R. Schuur

Summary: Liver disease is a major cause of global mortality, with late-stage liver disease being characterized by hepatocyte injury, inflammation, and aberrant tissue healing. Treatment options for liver disease are limited, but cell replacement therapy using hepatocyte-like cells shows promise as a safe and effective treatment option.

CELLS (2022)

Article Medicine, Research & Experimental

An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases

Christian T. Stackhouse, Joshua C. Anderson, Zongliang Yue, Thanh Nguyen, Nicholas J. Eustace, Catherine P. Langford, Jelai Wang, James R. Rowland, Chuan Xing, Fady M. Mikhail, Xiangqin Cui, Hasan Alrefai, Ryan E. Bash, Kevin J. Lee, Eddy S. Yang, Anita B. Hjelmeland, C. Ryan Miller, Jake Y. Chen, Yancey Gillespie, Christopher D. Willey

Summary: The key molecular regulators of acquired radiation resistance in recurrent glioblastoma (GBM) are largely unknown. In this study, patient-derived xenograft (PDX) models were generated to mimic the longitudinal evolution of patient recurrent tumors following radiation therapy. Whole-exome sequencing and bioinformatics analysis identified genomic alterations and kinomic alterations associated with acquired radiation resistance. The study also found multiple molecular routes to acquired radiation resistance and identified targetable kinases for potential therapeutic interventions. This research provides important insights into overcoming treatment resistance in GBM patients.

JCI INSIGHT (2022)

Article Gastroenterology & Hepatology

Barriers to Hepatitis C Virus Care and How Federally Qualified Health Centers Can Improve Patient Access to Treatment

David Lam, Robert J. Wong, Adla Tessier, Yenice Zapata, Elsie Saldana, Robert G. Gish

Summary: This study aimed to explore the impact of demographic-based and insurance-based barriers on HCV treatment access for the FQHC population. It found that insurance restrictions were the greatest challenge affecting treatment outcomes in the study population.

GASTROENTEROLOGY RESEARCH (2022)

Article Oncology

A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

David Levitz, Yogen Saunthararajah, Kateryna Fedorov, Lauren C. Shapiro, Ioannis Mantzaris, Aditi Shastri, Noah Kornblum, R. Alejandro Sica, Nishi Shah, Marina Konopleva, Kira Gritsman, Ira Braunschweig, Dennis L. Cooper, Kith Pradhan, Amit Verma, Eric J. Feldman, Mendel Gold Finger

Summary: The once-weekly dosing regimen of LDDec and VEN in AML and MDS patients shows promising activity, with high response rates and extended time on therapy compared to standard dosing HMA/VEN regimens, highlighting the importance of noncytotoxic DNA methyltransferase 1-targeting.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation

Jiani Chai, Jui Choudhuri, Qing Wang, Yanan Fang, Yang Shi, Josette Kamel, Nishi Shah, R. Alejandro Sica, Noah Kornblum, Marina Konopleva, Ioannis Mantzaris, Aditi Shastri, Kira Gritsman, Amit Verma, Mendel Goldfinger, Swati Goel, Yanhua Wang, Xuejun Tian

Summary: Although PD-L1 overexpression is observed in solid tumors, its expression patterns in acute myeloid leukemia (AML) are not well studied. This study shows that PD-L1 expression is significantly upregulated in AML cases with activating mutations in JAK2/STATs compared to wildtype controls. There is a positive correlation between phosphorylated STAT3 expression and PD-L1 expression. The CPS scoring system could be used to quantitatively measure PD-L1 expression in leukemias and JAK2/STATs mutant AML could be potential candidates for checkpoint inhibitor trials.

LEUKEMIA & LYMPHOMA (2023)

No Data Available